Xilio Therapeutics, Inc. Defined Contribution Plan, Cost
Xilio Therapeutics, Inc. (XLO) reported Defined Contribution Plan, Cost of $700.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-23.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:DefinedContributionPlanCostRecognized · last filed 2026-03-23
- Xilio Therapeutics, Inc. defined contribution plan, cost for fiscal 2025 was $700.00K, a 16.67% increase from fiscal 2024.
- Xilio Therapeutics, Inc. defined contribution plan, cost for fiscal 2024 was $600.00K, a 14.29% decline from fiscal 2023.
- Xilio Therapeutics, Inc. defined contribution plan, cost for fiscal 2023 was $700.00K, a 133.33% increase from fiscal 2022.
- Xilio Therapeutics, Inc. defined contribution plan, cost for fiscal 2022 was $300.00K.
| Period end | Defined Contribution Plan, Cost 12 month |
|---|---|
| 2025-12-31 | $700.00K 10-K · filed 2026-03-23 |
| 2024-12-31 | $600.00K 10-K · filed 2026-03-23 |
| 2023-12-31 | $700.00K 10-K · filed 2025-03-11 |
| 2022-12-31 | $300.00K 10-K · filed 2024-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 |